Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Arrowhead Pharmaceuticals stock | $65.85

Learn how to easily invest in Arrowhead Pharmaceuticals stock.

Arrowhead Pharmaceuticals Inc is a biotechnology business based in the US. Arrowhead Pharmaceuticals shares (ARWR) are listed on the NASDAQ and all prices are listed in US Dollars. Arrowhead Pharmaceuticals employs 232 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Arrowhead Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARWR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Arrowhead Pharmaceuticals stock price (NASDAQ: ARWR)

Use our graph to track the performance of ARWR stocks over time.

Arrowhead Pharmaceuticals shares at a glance

Information last updated 2021-10-24.
Latest market close$65.85
52-week range$55.57 - $93.66
50-day moving average $63.56
200-day moving average $68.92
Wall St. target price$87.92
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.22

Buy Arrowhead Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arrowhead Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arrowhead Pharmaceuticals price performance over time

Historical closes compared with the close of $65.85 from 2021-10-25

1 week (2021-10-18) -0.44%
1 month (2021-09-24) 0.73%
3 months (2021-07-26) -1.32%
6 months (2021-04-26) -11.61%
1 year (2020-10-26) 11.42%
2 years (2019-10-25) 70.82%
3 years (2018-10-26) 420.14%
5 years (2016-10-26) 970.73%

Is Arrowhead Pharmaceuticals under- or over-valued?

Valuing Arrowhead Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arrowhead Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Arrowhead Pharmaceuticals's EBITDA

Arrowhead Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.9 million.

The EBITDA is a measure of a Arrowhead Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Arrowhead Pharmaceuticals financials

Revenue TTM $107.6 million
Gross profit TTM $88 million
Return on assets TTM -13%
Return on equity TTM -27.09%
Profit margin -116.97%
Book value $4.19
Market capitalisation $6.9 billion

TTM: trailing 12 months

Shorting Arrowhead Pharmaceuticals shares

There are currently 3.2 million Arrowhead Pharmaceuticals shares held short by investors – that's known as Arrowhead Pharmaceuticals's "short interest". This figure is 10.1% up from 2.9 million last month.

There are a few different ways that this level of interest in shorting Arrowhead Pharmaceuticals shares can be evaluated.

Arrowhead Pharmaceuticals's "short interest ratio" (SIR)

Arrowhead Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Arrowhead Pharmaceuticals shares currently shorted divided by the average quantity of Arrowhead Pharmaceuticals shares traded daily (recently around 501334.63949843). Arrowhead Pharmaceuticals's SIR currently stands at 6.38. In other words for every 100,000 Arrowhead Pharmaceuticals shares traded daily on the market, roughly 6380 shares are currently held short.

However Arrowhead Pharmaceuticals's short interest can also be evaluated against the total number of Arrowhead Pharmaceuticals shares, or, against the total number of tradable Arrowhead Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arrowhead Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Arrowhead Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0359% of the tradable shares (for every 100,000 tradable Arrowhead Pharmaceuticals shares, roughly 36 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arrowhead Pharmaceuticals.

Find out more about how you can short Arrowhead Pharmaceuticals stock.

Arrowhead Pharmaceuticals share dividends

We're not expecting Arrowhead Pharmaceuticals to pay a dividend over the next 12 months.

Have Arrowhead Pharmaceuticals's shares ever split?

Arrowhead Pharmaceuticals's shares were split on a 1:10 basis on 16 November 2011. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arrowhead Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arrowhead Pharmaceuticals shares which in turn could have impacted Arrowhead Pharmaceuticals's share price.

Arrowhead Pharmaceuticals share price volatility

Over the last 12 months, Arrowhead Pharmaceuticals's shares have ranged in value from as little as $55.57 up to $93.66. A popular way to gauge a stock's volatility is its "beta".

ARWR.US volatility(beta: 1.26)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arrowhead Pharmaceuticals's is 1.2608. This would suggest that Arrowhead Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Arrowhead Pharmaceuticals overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.

Frequently asked questions

What percentage of Arrowhead Pharmaceuticals is owned by insiders or institutions?
Currently 3.176% of Arrowhead Pharmaceuticals shares are held by insiders and 65.569% by institutions.
How many people work for Arrowhead Pharmaceuticals?
Latest data suggests 232 work at Arrowhead Pharmaceuticals.
When does the fiscal year end for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals's fiscal year ends in September.
Where is Arrowhead Pharmaceuticals based?
Arrowhead Pharmaceuticals's address is: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105
What is Arrowhead Pharmaceuticals's ISIN number?
Arrowhead Pharmaceuticals's international securities identification number is: US04280A1007
What is Arrowhead Pharmaceuticals's CUSIP number?
Arrowhead Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 042797100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site